Table 1 Characteristics of each group
Characteristics | Control group (n = 59) | PBPM group (n = 110) | p-value |
|---|---|---|---|
Gender | 0.5033 | ||
Male, n (%) | 40 (67.3) | 80 (72.7) | |
Female, n (%) | 19 (32.2) | 30 (27.3) | |
Age (year), median (range) | 71.0 (60.0–84.0) | 71.0 (49.0–89.0) | 0.6601 |
ECOG performance status, n (%) | 2.8390 | ||
0 | 37 (62.7) | 90 (81.8) | |
1 | 17 (28.8) | 9 (8.2) | |
2 | 5 (8.5) | 1 (0.9) | |
Primary site of cancer, n (%) | 0.0007 | ||
Colorectal | 53 (89.8) | 110 (100) | |
Breast | 5 (8.5) | – | |
Stomach | 1 (1.7) | – | |
BSA (m2), median (range) | 1.70 (1.31–1.97) | 1.62 (1.24–2.05) | 0.0301 |
Daily dose of capecitabine, median (range) | 3000 (1200-3600) | 2400 (1200-4200) | 0.5894 |
Chemotherapy regimens, n (%) | 0.2509 | ||
XELOX | 34 (57.6) | 55 (50.0) | |
XELOX + Bevacizumab | 16 (27.1) | 30 (27.3) | |
Capecitabine | 9 (15.3) | 24 (21.8) | |
XELIRI + Bevacizumab | 0 (0) | 1 (0.9) | |
Laboratory data, median (range) | |||
Cr (mg/dL) | 0.69 (0.45–1.6) | 0.75 (0.37–1.51) | 0.1497 |
GFR (mL/min/1.78m2) | 76.8 (32.5–105.8) | 72.4 (6.5–143) | 0.2323 |
AST (U/L) | 31 (16–84) | 23 (11–71) | 2.4730 |
ALT (U/L) | 21 (9–47) | 15 (6–74) | 0.0046 |
WBC (/μL) | 4490 (2750-8070) | 4145 (2610-10,540) | 0.0097 |
Hb (g/dL) | 12.1 (6.3–16.6) | 12.0 (9.0–18.3) | 0.6454 |
RBC (106/μL) | 3.81 (1.7–5.4) | 3.9 (2.2–5.9) | 0.1067 |